The FDA has approved removal of a safety warning on the label of Smith & Nephew's Regranex gel that noted "increased rate of mortality secondary to malignancy." The decision came after several studies showed no increased safety risk from Regranex, which is indicated to treat lower extremity diabetic neuropathic ulcers.
FDA OKs removal of safety warning from Smith & Nephew's Regranex gel
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.